U.S. Antipsychotic Drugs Market by Disease (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, and Others), by Drug (Risperidone, Quetiapine, Olanzapine, Aripiprazole, Brexpiprazole, Paliperidone Palmitate, and Others), by Therapeutic Class (First Generation, Second Generation, and Third Generation), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), by United states (Northeast, Southeast, Midwest, Southwest, West) Forecast 2024-2032
The U.S. Antipsychotic Drugs Market size was valued at USD 7.49 USD Billion in 2023 and is projected to reach USD 11.56 USD Billion by 2032, exhibiting a CAGR of 6.4 % during the forecast period. Antipsychotic agents, in evaluable terms, are medications that help the management of severe psychotic symptoms of schizophrenia. They function by modifying the activity of neurotransmitters in the brain, mostly dopamine, to effect healing of the symptoms such as delusions, illusions, and disorganized thinking. Such psychiatrics can be classified into two types: typical (first-generation) and atypical (second-generation) neuroleptics. The next type of drugs used include the typical and atypical antipsychotics. The typical ones act by directly blocking the dopamine responses, while the atypical ones do so as well as others like serotonin. They’re also used to treat severe mood disorders, some types of dementia, and some non-psychotic disorders that present with psychotic symptoms.
August 2022: Acadia Pharmaceuticals Inc.’s antipsychotic drug approval for treating psychosis related to Alzheimer's disease was declined by the U.S. Food and Drug Administration.
December 2021: Intra-Cellular Therapies, Inc. received the U.S. FDA approval for CAPLYTA for depressive episodes linked with bipolar I or II disorder in adults. It is a monotherapy and adjunctive therapy with lithium or valproate.
September 2021: Sumitomo Dainippon Pharma’s- U.S.-based subsidiary Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Co., Ltd. collaborated and licensed agreement. The agreement aims to develop and commercialize the four novel candidate compounds currently developing in psychiatry and neurology.
This report covers the following:
The United States dominates the North American antipsychotic drugs market due to the high prevalence of mental health disorders and the availability of advanced healthcare infrastructure. Other key regional markets include Europe, Asia-Pacific, and Latin America.
D (Drivers): Rising prevalence of mental health disorders, technological advancements
R (Restraints): Side effects associated with antipsychotic drugs, generic competition, stigma
O (Opportunities): Personalized medicine, digital therapeutics, long-acting injections
C (Challenges): Access to treatment, affordability, drug abuse
T (Threats): Patent expirations, reimbursement policies
The pricing of antipsychotic drugs varies based on the brand, dosage, and distribution channel. Generic drugs are typically priced lower than brand-name drugs. Hospital pharmacies generally offer the lowest prices for antipsychotic drugs.
The United States imports a significant amount of antipsychotic drugs from other countries, including India, China, and Israel. Export data is not readily available.
By Disease:
By Drug:
By Therapeutic Class:
By Distribution Channel:
Several patents related to antipsychotic drugs are currently active in the United States. These patents cover the composition, formulation, and use of specific antipsychotic drugs.
Aspects | Details |
---|---|
Study Period | 2018-2032 |
Base Year | 2023 |
Estimated Year | 2024 |
Forecast Period | 2024-2032 |
Historical Period | 2018-2023 |
Growth Rate | CAGR of 6.4% from 2018-2032 |
Segmentation |
|
Office no. A 5010, fifth floor, Solitaire Business Hub, Near Phoenix mall, Pune, Maharashtra 411014
Craig Francis
Business Development Head
+44 1223 92 666
sales@advancemarketanalytics.com
get latest updates and offers.